Treating Other STDs May Reduce HIV Levels in the Semen
September 1st 1997CHAPEL HILL, NC-Men infected with HIV who also have another sexually transmitted disease (STD) have approximately an eightfold increase in the amount of HIV in their semen, compared with men who do not have a second sexually transmitted disease, a study conducted in Africa has shown.
Multidisciplinary Evaluation and Treatment: Evolution to Standard Clinical Practice
September 1st 1997Combined-modality therapy integrating chemotherapy with radiotherapy and/or surgery is playing an increasing role in the day-to-day management of a wide variety of solid tumors. No longer is this approach solely a clinical research tool. In fact, in
Trials of IV SNX-111 Paused, but Phase III Pain Trials Continue
September 1st 1997MENLO PARK, Calif-Neurex Corporation has announced a pause in enrollment of a trial of intravenous SNX-111 for patients with severe head trauma, to review data from earlier studies for overall risk/benefit. The agent is an N-type neuron-specific calcium blocker derived from the venom of the cone snail.
Patients, Physicians Need Info on Newer Lung Cancer Therapies
September 1st 1997NEW YORK-Today’s treatments for lung cancer are much better tolerated than treatments used 20 years ago, Robert Ginsberg, MD, chief of the Thoracic Service, Memorial Sloan-Kettering Cancer Center, said at an NIH video satellite symposium beamed to 20 selected centers nationwide.
Inhaled IL-2 Stabilizes Pulmonary Metastases of Renal Cell Cancer
September 1st 1997SAN FRANCISCO-The search for less invasive and less toxic methods to deliver interleukin-2 (IL-2) has moved beyond injection. Edith Huland, MD, PhD, of the University Clinic Eppendorf, Hamburg, Germany, has been using a nebulizer to deliver IL-2 for six years.
Outpatient Biochemotherapy Safe, Effective in Renal Cell Cancer
September 1st 1997SAN FRANCISCO-An outpatient combination of low-dose interleukin-2 (IL-2, Proleukin), interferon alfa-2b (Intron A), and fluorouracil appears to offer response and survival rates similar to high-dose IL-2 with minimal side effects, according to studies conducted by Jens Atzpodien, MD, associate professor of medicine, Medizinische Hochschule, Hannover, Germany.
Obstacles to Advance Directives May Include Physicians
September 1st 1997NEW YORK-The majority of people in the United States die without discussing or documenting their wishes regarding end-of-life care. Estimates of the number of people who have actually prepared advance directives range from 5% to 25%, said Sylvia Pearl, LCSW, during a national teleconference sponsored by Cancer Care, Inc.
Neuropsychiatric Syndromes Prevalent Among CNS Cancer Patients
September 1st 1997HOUSTON-Approximately 50% to 80% of patients with central nervous system tumors experience emotional and behavioral changes that significantly alter their capacity to function independently and interact in a healthy manner, Alan D. Valentine, MD, said at a symposium on cancer and the central nervous system. In fact, he added, behavioral changes may be one of the first signs that a patient is seriously ill.
Once-Daily Sustained-Release Morphine Effective for Cancer Pain
September 1st 1997ADELAIDE, Australia-A sustained-release morphine formulation that can be administered once or twice a day (Kadian) showed similar efficacy and safety to a standard twice-daily morphine formulation (MS Contin) in a multicen-ter, placebo-controlled US study of cancer pain patients, sponsored by the Australian manufacturers of Kadian.
Long-Term Dronabinol Use Safe, Effective for AIDS Anorexia
September 1st 1997COLUMBUS, Ohio-A new multi-center study supports the long-term use of dronabinol (Marinol) for anorexia associated with weight loss in patients with AIDS. Dronabinol is a synthetically produced delta-9-tetrahydrocannabinol, the active constituent of marijuana.
Cancer Patients Use Music to Soothe Presurgical Anxiety
September 1st 1997NEW ORLEANS-Surgical oncol-ogy patients appear to be overwhelmingly in favor of listening to music before and after their surgery. Besides its soothing powers, music may help in pain control, offering a cost-effective intervention, investigators reported at the Oncology Nursing Society.
FDA Approves Taxol for Use in AIDS-Related KS
September 1st 1997ROCKVILLE, Md-The Food and Drug Administration (FDA) has cleared Bristol-Myers Squibb’s Taxol (paclitaxel) Injection for use in the second-line treatment of AIDS-related Kaposi’s sarcoma (KS). Taxol is also approved for second-line use in metastatic breast and ovarian cancer.
AACR Urges Tobacco Industry Support of Cancer Research
September 1st 1997PHILADELPHIA-The proposed tobacco settlement should include support for federally funded cancer research “in proportion to the devastation caused by tobacco-induced cancers on our public health,” the American Association for Cancer Research said in a position statement.
Panel Gives Platelet Growth Factor Nod of Approval
September 1st 1997MADISON, NJ-The Biological Response Modifiers Advisory Committee unanimously recommended that the Food and Drug Administration approve Neumega (recombinant human inter-leukin-11 or rhIL-11), Genetics Institute’s platelet growth factor. Genetics Institute is a subsidiary of American Home Products Corporation.
Panel Recommends FDA Approve First MoAb for Cancer Rx
September 1st 1997BETHESDA, Md-The Biological Response Modifiers Advisory Committee has recommended that the FDA usher cancer therapy into a new era by approving IDEC Pharamceutical’s Rituxan (rituximab) for patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma.
Clinton Proposes New Law on Patient Privacy
September 1st 1997WASHINGTON-The Clinton Administration soon will propose a federal law aimed at protecting the privacy of medical records. The law would allow disclosure of medical records only for reasons of health care. For example, if an employer gained access to an employee’s records during the claims process, the company would not be allowed to use the information in any way that would affect the employee’s job, such as in considering promotions or assignments.